Physician profile
Mark Pressprich
NPI 1194288944
$15,367.60
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $1,911 · 2024: $837 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,474 · Food and Beverage: $3,693 · Travel and Lodging: $2,914 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,473.75 |
| Food and Beverage | $3,693.09 |
| Travel and Lodging | $2,914.36 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $9,263.32 | 2024-2025 | Erleada, Akeega |
| Boston Scientific Corporation | $2,004.48 | 2023-2025 | Ams 700, Axonics, Ams 800 Artificial Urinary Sphincter |
| Janssen Scientific Affairs, LLC | $1,339.62 | 2025 | Erleada |
| Medtronic, INC. | $424.95 | 2022-2024 | Interstim |
| Biotissue Holdings INC. | $313.31 | 2025 | |
| Calyxo, INC. | $242.32 | 2024-2025 | Cvac Aspiration System |
| Abbvie INC. | $227.63 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $182.28 | 2024-2025 | Orgovyx, Gemtesa |
| Telix Pharmaceuticals | $137.50 | 2024 | Illuccix |
| Coloplast Corp | $123.96 | 2024-2025 | |
| Olympus America INC. | $123.01 | 2022-2025 | Itind System, Bovie |
| Tempus Ai, INC | $112.18 | 2024-2025 | Xt Cdx |
| Antares Pharma, INC. | $109.24 | 2024-2025 | Xyosted |
| Teleflex LLC | $109.18 | 2024-2025 | Barrigel, Urolift |
| Astellas Pharma US INC | $108.03 | 2024-2025 | Xtandi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $97.37 | 2024-2025 | Eligard, Jatenzo |
| Myriad Genetic Laboratories, INC. | $66.29 | 2024-2025 | Prolaris, Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $60.74 | 2025 | |
| Axonics, INC. | $54.69 | 2023-2024 | Axonics, Bulkamid |
| Pfizer INC. | $40.95 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $30.94 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $30.52 | 2024 | |
| Urogen Pharma, INC. | $25.94 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $22.62 | 2025 | Lynparza |
| Endo USA, INC. | $20.44 | 2025 | Xiaflex |
| Verity Pharmaceuticals INC. | $19.04 | 2025 | Tlando |
| Smith+Nephew, INC. | $18.03 | 2025 | Stravix Pl |
| Accord Healthcare, INC. | $16.20 | 2024 | |
| Laborie Medical Technologies Corp. | $15.09 | 2025 | |
| Ambu INC. | $14.09 | 2025 | |
| Photocure INC | $13.64 | 2025 | Cysview |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pressprich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.